Faculty

Dr. Poonkuzhali Balasubramanian

Dr. Poonkuzhali Balasubramanian, M.Sc, PhD

Professor, Department of Hematology

Professor, Department of Hematology
Wellcome DBT Senior Fellow
Christian Medical College
Vellore- 632004, Tamilnadu, INDIA.
Phone: +91 416 2283476
Fax : 91-416-2226449
e-mail : bpoonkuzhali@cmcvellore.ac.in 

Pharmacogenetics of anticancer agents, Molecular genetics of leukemia, Anticancer drug resistance, Conditioning regimen in hematopoietic stem cell transplantation

Research interests

Anticancer Drug Resistance- Mechanisms and Modulation

We are trying to understand the mechanisms of anticancer drug resistance in myeloid leukemias. Acute myeloid leukemia (AML) is a biologically, clinically and genetically heterogeneous disease characterized by increased proliferation and defective maturation affecting the cells of the myeloid lineage. The backbone of AML treatment for the last 30 years has been the combination of daunorubicin and cytosine arabinoside (Ara-C). The BCR/ABL tyrosine kinase Imatinib mesylate (IM) is the mainstay of treatment for CML but does not eliminate primitive leukemia stem and progenitor cells. Residual leukemia cells are a potential source of relapse, and there is considerable interest in identifying additional therapeutic targets to selectively induce apoptosis in leukemic stem and progenitor cells. We attempt to extend the understanding of novel biology of leukemias with an effort to understand potential novel targets in AML, as well as to better understand mechanisms of resistance and intolerance to therapy in Chronic myeloid leukemia (CML). Our research is proposed to identify novel NHR genes as drug targets to overcome drug resistance in myeloid leukemias.

Targeted therapy with BCR-ABL tyrosine kinase inhibitors has tremendously improved the outcome of chronic myeloid leukemia (CML). However, about 15-20% patients treated with imatinib develop resistance or intolerance to the drug resulting in disease progression. Hence adequate molecular tools are required to diagnose, prognosticate and monitor minimal residual disease to make appropriate decisions on continuing therapy or changing. This decision process is compounded by the high cost of these second generation drugs in a predominantly self-paying system as exists in our country. In this project we plan to work towards an integrated model with a combination of the existing and novel parameters to more accurately prognosticate response to therapy in these patients. We believe that such a model working towards a cost effective therapy in patients with CML is critical for patients in our country where the cost of second generation TKI is prohibitive for most. Using a multidisciplinary approach, we anticipate that this study will have sufficient strength to arrive at genetic/prognostic signatures to identify poor responders and personalize therapy which could result in better treatment outcome. By exploring the mechanisms of disease progression, intolerance and resistance to imatinib using various genomic and cellular approaches, we anticipate that this study will eventually aid in personalizing tyrosine kinase inhibitor therapy in this disease.

Personalizing conditioning regimen in hematopoietic stem cell transplantation

Another major area of research in our laboratory is personalizing the conditioning regimen used in preparing patients for haematopoietic stem cell transplantation. Please see the link below for more details.
( www.wellcomedbt.org/fellowsprofile/main/research/id/237)

Team

Research Fellows

  • Balaji Balakrishnan
  • Saswati Das
  • Stallon Illangeswaran
  • Sreeja Karathedath
  • Ezhilpavai Mohanan
  • shwin A Pai
  • Bharathi Rajamani
  • Esther Sathyabama

Research Technicians

  • Amirthavani
  • Alex

Alumni

Research Fellows:

  • Ajay Abraham, Postdoctoral fellow, University of Alabama at Birmingham
  • Sukanya Ganesan
  • Lakshmi Kailasam
  • Preetha Markose, Research Professional, University of the Sciences in Philadelphia
  • Ayisha Sithika M
  • Pravani Sukumaran
  • Savitha Varatharajan

Short term project students

  • Keshav Bharadwaj, Shoolini University, Himachal Pradesh
  • Sudershan Dhiman, Shoolini University, Himachal Pradesh
  • Dantuluri Swati, VIT Vellore
  • Vrindha Ghambir, VIT Vellore
  • Stavan Arulanand, Amity University, New Delhi
  • Shravanthi, PSG Coimbatore
  • Nisha Jain, VIT Vellore

Research Support: Ongoing Research Projects as Principal Investigator-4

Title of Project<> Funding Agency Amount (Lakhs) Date of sanction and Duration
Personalizing conditioning regimen in hematopoietic stem cell transplantation Wellcome DBT 445 Oct 2015 -2020
Identification of novel nuclear receptors (NHR) drug targets in myeloid leukemia DBT 75.75 Nov 2015 -2020
Exploring the mechanisms of disease progression, tyrosine kinase inhibitor resistance and intolerance in Chronic Myeloid Leukemia DBT 83.65 Nov 2015 -2020

Completed Research Projects

    >
  • Pharmacogenetics of cytarabine and Daunorubicin in acute myeloid leukemia, funded by DBT, India, part of “DBT Programme support”, 2009-2014, Principal Investigator.
  • Mechanisms of Imatinib resistance in chronic myeloid leukemia- funded by DBT, India, part of “DBT Programme support”, 2009-2014, Principal Investigator.
  • Evaluation of prognostic markers in patients with acute myeloid leukemia- funded by DBT, India, part of “DBT Programme support”, 2009-2014, Co- principal Investigator
  • “Pharmacogenetics of cytarabine and Daunorubicin Resistance in the Leukemic Stem Cell Compartment in acute myeloid leukemia”- INSERM-ICMR, Jan 2011- December 2012; Principal Investigator.

Education (Post-Graduation onwards & Professional Career)

Degree University/College Year Field of Study
Master of Science (Biochemistry) Madras University 1990-1992 Clinical Biochemistry
Ph.D. (Biochemistry) Christian Medical College, Vellore
Tamilnadu Dr. MGR Medical University
1995-1999 Biochemistry/ Pharmacology-Pharmacokinetics
Post-Doctoral Fellowship St Jude Children’s Research Hospital
Memphis, TN, USA
2007 Pharmaceutical Sciences/Pharmacogenetics
Post-Doctoral Fellowship University of Chicago 2007 March-September Pharmacogenetics/Pediatrics

Position and Honors (Position and Employment (Starting with the most recent employment)

University/College Position From (Date) To (date)
Christian Medical College, Vellore Professor November 2008 Till date
Christian Medical College, Vellore Associate Professor November 2006 November 2008
Christian Medical College, Vellore Reader November 2004 November 2006
St Jude Children’s Research Hospital, Memphis, Tennessee-USA Post-Doctoral Research Associate September 2004 February 2007
University of Chicago, Chicago, Illinois, USA Research Professional March 2007 September 2007

Selected Peer reviewed Publications

  • Frequency of rare BCR-ABL fusion transcripts in chronic myeloid leukemia patients. Arun Kumar A, Senthamizhselvi A, Sathya M, Vinodhini K, Nancy Beryl Janet A, Aby Abraham, Biju George, Alok Srivastava, Vivi M Srivastava, Vikram Mathews, Poonkuzhali Balasubramanian. Int J Lab Hematol. 2016 (In Press)
  • ABC Transporter Expression in Acute Myeloid Leukemia: Association with in-vitro Cytotoxicity and Prognostic Markers. Savitha Varatharajan, Ajay Abraham, Sreeja Karathedath, Sukanya Ganesan, Kavitha M. Lakshmi, Nancy Arthur, Vivi M Srivastava, Biju George, Alok Srivastava, Vikram Mathews, Poonkuzhali Balasubramanian. Pharmacogenomics 2016 (In Press)
  • Rationale and efficacy of proteasome inhibitor combined with arsenic trioxide in the treatment of acute promyelocytic leukemia. Ganesan S, Alex AA, Chendamarai E, Balasundaram N, Palani HK, David S, Kulkarni U, Aiyaz M, Mugasimangalam R, Korula A, Abraham A, Srivastava A, Padua RA, Chomienne C, George B, Balasubramanian P, Mathews V. Leukemia. 2016 Nov;30(11):2169-2178. doi: 10.1038/leu.2016.227. PMID: 27560113
  • Population pharmacokinetics of Daunorubicin in adult patients with acute myeloid leukemia. Varatharajan S, Panetta JC, Abraham A, Karathedath S, Mohanan E, Lakshmi KM, Arthur N, Srivastava VM, Nemani S, George B, Srivastava A, Mathews V, Balasubramanian P. Cancer Chemother Pharmacol. 2016 Nov;78(5):1051-1058. PMID: 27738808
  • Atypical BCR-ABL1 fusion transcripts in adult B-acute lymphoblastic leukemia, including a novel fusion transcript-e8a1. Deshpande PA, Srivastava VM, Mani S, Anandhan S, Meena J, Abraham A, Viswabandya A, George B, Srivastava A, Mathews V, Balasubramanian P. Leuk Lymphoma. 2016 Oct;57(10):2481-4. doi: 10.3109/10428194.2016.1151512. No abstract available. PMID: 26942999
  • Treatment rates of paediatric acute myeloid leukaemia: a view from three tertiary centres in India - response to Gupta et al. Philip C, George B, Korula A, Srivastava A, Balasubramanian P, Mathews V. Br J Haematol. 2016 Oct;175(2):347-349. doi: 10.1111/bjh.13857. No abstract available. PMID: 26627639
  • RNA expression of genes involved in cytarabine metabolism and transport predicts cytarabine response in acute myeloid leukemia. Abraham A, Varatharajan S, Karathedath S, Philip C, Lakshmi KM, Jayavelu AK, Mohanan E, Janet NB, Srivastava VM, Shaji RV, Zhang W, Abraham A, Viswabandya A, George B, Chandy M, Srivastava A, Mathews V, Balasubramanian P. Pharmacogenomics. 2015 Jul;16(8):877-90. doi: 10.2217/pgs.15.44. PMID: 26083014
  • Acute myeloid leukaemia: challenges and real world data from India. Philip C, George B, Ganapule A, Korula A, Jain P, Alex AA, Lakshmi KM, Sitaram U, Abubacker FN, Abraham A, Viswabandya A, Srivastava VM, Srivastava A, Balasubramanian P, Mathews V. Br J Haematol. 2015 Jul;170(1):110-7. doi: 10.1111/bjh.13406. PMID: 25858293
  • Comparison of newly diagnosed and relapsed patients with acute promyelocytic leukemia treated with arsenic trioxide: insight into mechanisms of resistance. Chendamarai E, Ganesan S, Alex AA, Kamath V, Nair SC, Nellickal AJ, Janet NB, Srivastava V, Lakshmi KM, Viswabandya A, Abraham A, Aiyaz M, Mullapudi N, Mugasimangalam R, Padua RA, Chomienne C, Chandy M, Srivastava A, George B, Balasubramanian P, Mathews V. PLoS One. 2015 Mar 30;10(3):e0121912. doi: 10.1371/journal.pone.0121912. PMID: 25822503
  • V-raf murine sarcoma viral oncogene homolog B (BRAF) mutations in hairy cell leukaemia. Arora N, Nair S, Pai R, Nair S, Ahmed R, Abraham A, Viswabandya A, George B, Balasubramanian P, Srivastava A, Mathews V. Indian J Pathol Microbiol. 2015 Jan-Mar;58(1):62-5. doi: 10.4103/0377-4929.151190. PMID: 25673595
  • Effect of cytosine arabinoside metabolizing enzyme expression on drug toxicity in acute myeloid leukemia. Abraham A, Devasia AJ, Varatharajan S, Karathedath S, Balasubramanian P, Mathews V. Ann Hematol. 2015 May;94(5):883-5. doi: 10.1007/s00277-014-2254-2. No abstract available. PMID: 25391240
  • Genetic association between the DRD4 promoter polymorphism and clozapine-induced sialorrhea. Rajagopal V, Sundaresan L, Rajkumar AP, Chittybabu C, Kuruvilla A, Srivastava A, Balasubramanian P, Jacob KS, Jacob M. Psychiatr Genet. 2014 Dec;24(6):273-6. doi: 10.1097/YPG.0000000000000058. PMID: 25304228
  • ABCB6 RNA expression in leukemias--expression is low in acute promyelocytic leukemia and FLT3-ITD-positive acute myeloid leukemia. Abraham A, Karathedath S, Varatharajan S, Markose P, Chendamarai E, Jayavelu AK, George B, Srivastava A, Mathews V, Balasubramanian P. Ann Hematol. 2014 Mar;93(3):509-12. doi: 10.1007/s00277-013-1821-2. No abstract available. PMID: 23793916
  • Novel NPM1 mutation in the 3'-untranslated region identified in two patients with acute myeloid leukemia. Abraham A, Karathedath S, Kumaraswamy V, Jayavelu AK, Mani S, Srivastava VM, Zhang W, Zhou T, George B, Srivastava A, Mathews V, Balasubramanian P. Leuk Lymphoma. 2014 Jun;55(6):1421-4. doi: 10.3109/10428194.2013.838235. No abstract available. PMID: 23998253
  • A rapid & sensitive liquid chromatography- tandem mass spectrometry method for the quantitation of busulfan levels in plasma & application for routine therapeutic monitoring in haematopoietic stem cell transplantation. Desire S, Mohanan EP, George B, Mathews V, Chandy M, Srivastava A, Balasubramanian P. Indian J Med Res. 2013 Apr;137(4):777-84. PMID: 23703347
  • Role of imatinib in the treatment of pediatric onset indolent systemic mastocytosis: a case report. Agarwala MK, George R, Mathews V, Balasubramanian P, Thomas M, Nair S. J Dermatolog Treat. 2013 Dec;24(6):481-3. doi: 10.3109/09546634.2013.802274. PMID: 23659595
  • Association between CYP1A2 gene single nucleotide polymorphisms and clinical responses to clozapine in patients with treatment-resistant schizophrenia. Rajkumar AP, Poonkuzhali B, Kuruvilla A, Srivastava A, Jacob M, Jacob KS. Acta Neuropsychiatr. 2013 Feb;25(1):2-11. doi: 10.1111/j.1601-5215.2012.00638.x. PMID: 26953068
  • Clinical predictors of serum clozapine levels in patients with treatment-resistant schizophrenia. Rajkumar AP, Poonkuzhali B, Kuruvilla A, Jacob M, Jacob KS. Int Clin Psychopharmacol. 2013 Jan;28(1):50-6. doi: 10.1097/YIC.0b013e32835ac9da. PMID: 23104241
  • Outcome definitions and clinical predictors influence pharmacogenetic associations between HTR3A gene polymorphisms and response to clozapine in patients with schizophrenia. Rajkumar AP, Poonkuzhali B, Kuruvilla A, Srivastava A, Jacob M, Jacob KS. Psychopharmacology (Berl). 2012 Dec;224(3):441-9. doi: 10.1007/s00213-012-2773-2. PMID: 22700043
  • Carbonyl reductase 1 expression influences daunorubicin metabolism in acute myeloid leukemia. Varatharajan S, Abraham A, Zhang W, Shaji RV, Ahmed R, Abraham A, George B, Srivastava A, Chandy M, Mathews V, Balasubramanian P. Eur J Clin Pharmacol. 2012 Dec;68(12):1577-86. doi: 10.1007/s00228-012-1291-9. PMID: 22562609
  • Role of minimal residual disease monitoring in acute promyelocytic leukemia treated with arsenic trioxide in frontline therapy. Chendamarai E, Balasubramanian P, George B, Viswabandya A, Abraham A, Ahmed R, Alex AA, Ganesan S, Lakshmi KM, Sitaram U, Nair SC, Chandy M, Janet NB, Srivastava VM, Srivastava A, Mathews V. Blood. 2012 Apr 12;119(15):3413-9. doi: 10.1182/blood-2011-11-393264. PMID: 22374701
  • Cytidine deaminase genetic variants influence RNA expression and cytarabine cytotoxicity in acute myeloid leukemia. Abraham A, Varatharajan S, Abbas S, Zhang W, Shaji RV, Ahmed R, Abraham A, George B, Srivastava A, Chandy M, Mathews V, Balasubramanian P. Pharmacogenomics. 2012 Feb;13(3):269-82. doi: 10.2217/pgs.11.149. PMID: 22304580
  • International reporting scale of BCR-ABL1 fusion transcript in chronic myeloid leukemia: first report from India. Balasubramanian P, Chendamarai E, Markose P, Fletcher L, Branford S, George B, Mathews V, Chandy M, Srivastava A. Acta Haematol. 2012;127(3):135-42. doi: 10.1159/000334716. PMID: 22249155
  • Population pharmacokinetics of cyclophosphamide in patients with thalassemia major undergoing HSCT. Balasubramanian P, Desire S, Panetta JC, Lakshmi KM, Mathews V, George B, Viswabandya A, Chandy M, Krishnamoorthy R, Srivastava A. Bone Marrow Transplant. 2012 Sep;47(9):1178-85. doi: 10.1038/bmt.2011.254. PMID: 22231460
  • Cytogenetic analysis of acute myeloid leukemia with t(8;21) from a tertiary care center in India with correlation between clinicopathologic characteristics and molecular analysis. Parihar M, Kumar JA, Sitaram U, Balasubramanian P, Abraham A, Viswabandya A, George B, Mathews V, Srivastava A, Srivastava VM. Leuk Lymphoma. 2012 Jan;53(1):103-9. doi: 10.3109/10428194.2011.603447. PMID: 21745004
  • Mast cell sarcoma of the small intestine: a case report. Bugalia A, Abraham A, Balasubramanian P, Srivastava A, Nair S. J Clin Pathol. 2011 Nov;64(11):1035-7. doi: 10.1136/jclinpath-2011-200154. No abstract available. PMID: 21778298
  • Clinical Predictors of Response to Clozapine in Patients with Treatment Resistant Schizophrenia. Anto Praveen Rajkumar, Chitra C, S Bhuvaneswari, Poonkuzhali B, Anju Kuruvilla, K.S. Jacob. Psychopharmacol Bull. 2011 Sep 15;44(3):51-65. Review. PMID: 27738362
  • The t(6;9)(p22;q34) in myeloid neoplasms: a retrospective study of 16 cases. Gupta M, Ashok Kumar J, Sitaram U, Neeraj S, Nancy A, Balasubramanian P, Abraham A, Mathews V, Viswabandya A, George B, Chandy M, Srivastava A, Srivastava VM. Cancer Genet Cytogenet. 2010 Dec;203(2):297-302. doi: 10.1016/j.cancergencyto.2010.08.012. PMID: 21156248
  • Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data. Mathews V, George B, Chendamarai E, Lakshmi KM, Desire S, Balasubramanian P, Viswabandya A, Thirugnanam R, Abraham A, Shaji RV, Srivastava A, Chandy M. J Clin Oncol. 2010 Aug 20;28(24):3866-71. doi: 10.1200/JCO.2010.28.5031. PMID: 20644086
  • Frequency of TPMT alleles in Indian patients with acute lymphatic leukemia and effect on the dose of 6-mercaptopurine. Desire S, Balasubramanian P, Bajel A, George B, Viswabandya A, Mathews V, Srivastava A, Chandy M. Med Oncol. 2010 Dec;27(4):1046-9. doi: 10.1007/s12032-009-9331-8. PMID: 19830600
  • Spectrum of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia from India with suspected resistance to imatinib-mutations are rare and have different distributions. Markose P, Chendamarai E, Balasubramanian P, Velayudhan SR, Srivastava VM, Mathews V, George B, Viswabandya A, Srivastava A, Chandy M. Leuk Lymphoma. 2009 Dec;50(12):2092-5. doi: 10.3109/10428190903332486. No abstract available. PMID: 19925053
  • Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen. Thirugnanam R, George B, Chendamarai E, Lakshmi KM, Balasubramanian P, Viswabandya A, Srivastava A, Chandy M, Mathews V. Biol Blood Marrow Transplant. 2009 Nov;15(11):1479-84. doi: 10.1016/j.bbmt.2009.07.010. PMID: 19822309
  • Identification of compounds that correlate with ABCG2 transporter function in the National Cancer Institute Anticancer Drug Screen. Deeken JF, Robey RW, Shukla S, Steadman K, Chakraborty AR, Poonkuzhali B, Schuetz EG, Holbeck S, Ambudkar SV, Bates SE. Mol Pharmacol. 2009 Nov;76(5):946-56. doi: 10.1124/mol.109.056192. PMID: 19633067
  • Transporter-mediated protection against thiopurine-induced hematopoietic toxicity. Krishnamurthy P, Schwab M, Takenaka K, Nachagari D, Morgan J, Leslie M, Du W, Boyd K, Cheok M, Nakauchi H, Marzolini C, Kim RB, Poonkuzhali B, Schuetz E, Evans W, Relling M, Schuetz JD. Cancer Res. 2008 Jul 1;68(13):4983-9. doi: 10.1158/0008-5472.CAN-07-6790. PMID: 18593894
  • Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. Rudin CM, Liu W, Desai A, Karrison T, Jiang X, Janisch L, Das S, Ramirez J, Poonkuzhali B, Schuetz E, Fackenthal DL, Chen P, Armstrong DK, Brahmer JR, Fleming GF, Vokes EE, Carducci MA, Ratain MJ. J Clin Oncol. 2008 Mar 1;26(7):1119-27. doi: 10.1200/JCO.2007.13.1128. PMID: 18309947
  • Association of breast cancer resistance protein/ABCG2 phenotypes and novel promoter and intron 1 single nucleotide polymorphisms. Poonkuzhali B, Lamba J, Strom S, Sparreboom A, Thummel K, Watkins P, Schuetz E. Drug Metab Dispos. 2008 Apr;36(4):780-95. doi: 10.1124/dmd.107.018366. PMID: 18180275
  • A common polymorphism in the bile acid receptor farnesoid X receptor is associated with decreased hepatic target gene expression. Marzolini C, Tirona RG, Gervasini G, Poonkuzhali B, Assem M, Lee W, Leake BF, Schuetz JD, Schuetz EG, Kim RB. Mol Endocrinol. 2007 Aug;21(8):1769-80. PMID: 17519356
  • Developing an algorithm of informative markers for evaluation of chimerism after allogeneic bone marrow transplantation. Sellathamby S, Balasubramanian P, Sivalingam S, Shaji RV, Mathews V, George B, Viswabandya A, Srivastava A, Chandy M. Bone Marrow Transplant. 2006 Apr;37(8):751-5. PMID: 16518431
  • Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Mathews V, George B, Lakshmi KM, Viswabandya A, Bajel A, Balasubramanian P, Shaji RV, Srivastava VM, Srivastava A, Chandy M. Blood. 2006 Apr 1;107(7):2627-32. PMID: 16352810
  • Randomized trial of two different conditioning regimens for bone marrow transplantation in thalassemia--the role of busulfan pharmacokinetics in determining outcome. Chandy M, Balasubramanian P, Ramachandran SV, Mathews V, George B, Dennison D, Krishnamoorthy R, Srivastava A. Bone Marrow Transplant. 2005 Nov;36(10):839-45. PMID: 16151422
  • Cytochrome P4501A1 and glutathione S transferase gene polymorphisms in patients with aplastic anemia in India. Poonkuzhali B, Shaji RV, Salamun DE, George B, Srivastava A, Chandy M. Acta Haematol. 2005;114(3):127-32. PMID: 16227674
  • Hematological and molecular remission with combination chemotherapy in a patient with PLZF-RARalpha acute promyelocytic leukemia (APML). George B, Poonkuzhali B, Srivastava VM, Chandy M, Srivastava A.Ann Hematol. 2005 Jun;84(6):406-8. PMID: 15592671
  • Treatment of children with newly diagnosed acute promyelocytic leukemia with arsenic trioxide: a single center experience. George B, Mathews V, Poonkuzhali B, Shaji RV, Srivastava A, Chandy M. Leukemia. 2004 Oct;18(10):1587-90. PMID: 15356649
  • Glutathione S-transferase M1 polymorphism: a risk factor for hepatic venoocclusive disease in bone marrow transplantation. Srivastava A, Poonkuzhali B, Shaji RV, George B, Mathews V, Chandy M, Krishnamoorthy R. Blood. 2004 Sep 1;104(5):1574-7. PMID: 15142875
  • Molecular remission with arsenic trioxide in patients with newly diagnosed acute promyelocytic leukemia. George B, Mathews L, Balasubramanian P, Shaji RV, Srivastava A, Chandy M. Haematologica. 2004 Oct;89(10):1266-7. PMID: 15477216
  •  
  • Rapid detection of beta-globin gene mutations and polymorphisms by temporal temperature gradient gel electrophoresis. Shaji RV, Edison ES, Poonkuzhali B, Srivastava A, Chandy M. Clin Chem. 2003 May;49(5):777-81. PMID: 12709369
  • Arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: a single center experience. Mathews V, Balasubramanian P, Shaji RV, George B, Chandy M, Srivastava A. Am J Hematol. 2002 Aug;70(4):292-9. PMID: 12210810
  • Cytogenetic, fluorescent in situ hybridization & reverse transcriptase-polymerase chain reaction analysis in acute promyelocytic leukaemia patients. Shivakumar S, Poonkhuzhali B, Gunasekaran S, Srivastava A, Chandy M. Indian J Med Res. 2002 Feb;115:59-67. PMID: 12138666
  • Evaluation of existing limited sampling models for busulfan kinetics in children with beta thalassaemia major undergoing bone marrow transplantation. Balasubramanian P, Chandy M, Krishnamoorthy R, Srivastava A. Bone Marrow Transplant. 2001 Nov;28(9):821-5. PMID: 11781641
  • Central nervous system relapse in a patient with acute promyelocytic leukaemia treated with arsenic tri-oxide. Mathews V, Balasubramanian P, Shaji RV, George B, Chandy M, Srivastava A. Br J Haematol. 2001 Apr;113(1):257-8. No abstract available. PMID: 11360894
  • Stability of busulfan in frozen plasma and whole blood samples. Balasubramanian P, Srivastava A, Chandy M. Clin Chem. 2001 Apr;47(4):766-8. No abstract available. PMID: 11274036
  • Glutathione S-transferase activity influences busulfan pharmacokinetics in patients with beta thalassemia major undergoing bone marrow transplantation. Poonkuzhali B, Chandy M, Srivastava A, Dennison D, Krishnamoorthy R. Drug Metab Dispos. 2001 Mar;29(3):264-7. PMID: 11181493
  • Pharmacokinetics of oral busulphan in children with beta thalassaemia major undergoing allogeneic bone marrow transplantation. Poonkuzhali B, Srivastava A, Quernin MH, Dennison D, Aigrain EJ, Kanagasabapathy AS, Krishnamoorthy R, Chandy M. Bone Marrow Transplant. 1999 Jul;24(1):5-11.PMID: 10435727
  • High-performance liquid chromatographic method for quantification of busulfan in plasma after derivatization by tetrafluorothiophenol. Quernin MH, Poonkuzhali B, Médard Y, Dennison D, Srivastava A, Krishnamoorthy R, Chandy M, Jacqz-Aigrain E. J Chromatogr B Biomed Sci Appl. 1999 Jan 8;721(1):147-52. PMID: 10027646
  • Quantification of busulfan in plasma by gas chromatography-mass spectrometry following derivatization with tetrafluorothiophenol. Quernin MH, Poonkuzhali B, Montes C, Krishnamoorthy R, Dennison D, Srivastava A, Vilmer E, Chandy M, Jacqz-Aigrain E. J Chromatogr B Biomed Sci Appl. 1998 May 8;709(1):47-56. PMID: 9653925
  • Comparison of HPLC & EMIT methods of cyclosporine assay in blood after bone marrow transplantation. Poonkuzhali B, Victoria J, Selvakumar R, Dennison D, Srivastava A, Jeyaseelan L, Chandy M, Kanagasabapathy AS. Indian J Med Res. 1995 Jul;102:39-41. PMID: 7558209
  • Effect of uric acid on sodium oxalate-induced urolithiasis in rats--biochemical and histological evidences. Poonkuzhali B, Saraswathi CP, Rajalakshmi K. Indian J Exp Biol. 1994 Jan;32(1):20-4. PMID: 8045600